SELECTED PUBLICATIONS
The publications below feature research supported by Rincon Bio’s preclinical oncology services. They include xenograft efficacy studies, syngeneic tumor models, and evaluations of antibody–drug conjugates and cancer immunotherapies. Each entry identifies Rincon’s documented contribution.
2026
NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models
Cancer Cell International · 2026
The publication identifies Rincon Bio as the site of experimental tumor studies evaluating antibody–drug conjugates targeting NPTXR.
Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth
Frontiers in Oncology · 2026
The authors acknowledge Rincon Bio among the research providers supporting the in vivo studies.
2025
Hi-C profiling in tissues reveals 3D chromatin-regulated breast tumor heterogeneity informing a looping-mediated therapeutic avenue
Cell Reports · 2025
The methods identify Rincon Biosciences as the site of mouse experiments supporting research into breast cancer and resistance to tamoxifen.
2024
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates
Journal of Medicinal Chemistry · 2024
The authors acknowledge Rincon Bio for conducting xenograft studies evaluating antibody–drug conjugates incorporating a novel linker design.
Sol-moiety: Discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics
Nature Communications · 2024
Rincon Bio performed BxPC-3 pancreatic cancer xenograft efficacy studies supporting the evaluation of an orally administered paclitaxel prodrug.
2023
Translational Studies Using the MALT1 Inhibitor (S)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer
Journal of Immunotherapy and Precision Oncology · 2023
The study evaluates MALT1 inhibition alone and in combination with anti-PD-1 therapy in MC38, D4M.3A, and B16.F10 syngeneic tumor models. The methods identify Rincon Bio’s Institutional Animal Care and Use Committee approval for the animal experiments.
2022
Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy
Cancer Research Communications · 2022
The authors acknowledge Rincon Bio LLC and Xentech SAS for performing in vivo studies supporting the evaluation of EVT801.
2021
Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody–Drug Conjugates
Molecular Pharmaceutics · 2021
The authors acknowledge Dr. Bret Stephens of Rincon Bioscience, LLC for assistance with the xenograft assay supporting the evaluation of AJICAP antibody–drug conjugation technology.
2020
Synthesis and Biological Evaluation of Antibody Drug Conjugates Based on an Antibody Expression System: Conamax
ACS Omega · 2020
The authors acknowledge Dr. Bret Stephens of Rincon Bioscience, LLC for assistance with the xenograft assay. The study evaluates anti-HER2 antibody–drug conjugates in an NCI-N87 gastric cancer model.
Email: info@rinconbio.com
Tel: 760-713-6613
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
California:
3156 Vista Way, Suite 220
Oceanside, CA 92056